HIV infection follows an extremely variable course, with some individuals staying healthy for more than 15 years while others may become ill and die in fewer than five years. Overall, about one of every five HIV positive people is healthy with no symptoms of HIV after 10 years of infection. A small percentage of HIV positive people have identifiable genetic or virus-related factors identified that may explain the slow (or fast) progression of HIV disease; however, these disease-modifying factors are not common and thus do not explain most of the variability in HIV disease. GB Virus type C (GBV-C) is a human virus that was discovered in 1995. It rapidly became clear that the virus is very common in healthy people. Although GBVC persists in about one in every two to three people infected, extensive studies failed to demonstrate an association with any illness. GBV-C grows in CD4+ T lymphocytes, the same cell that HIV grows in. A number of studies found that HIV-positive people have a very high rate of active (39%) or prior (46%) infection with GBV-C, and furthermore, that HIV-positive people who are co-infected with GBV-C appear to live longer than HIV-positive patients without GBV-C infection. Recently, the Multicenter AIDS Cohort Study group (MACS) tested the best-characterized group of HIV-positive patients in the world, and confirmed that GBV-C infection was associated with prolonged survival, confirmed. In addition, the MACS study found that about 20% of the GBV-C and HIV co-infected individuals lost evidence of GBV-C infection during follow up. Individuals who """"""""lost"""""""" the GB virus were almost 6 times more likely to die than those who continued to have active GBV-C infection. We propose to study three large, multicenter cohorts to try to determine why some people lose GBV-C infection. In addition, we will study the association between GBV-C and improved survival in different gender, racial, and ethnic groups. Finally, we will perform exploratory studies designed to identify how GBV-C may improve survival in HIV-positive people. We suspect that it is due to an anti-HIV effect and/or an effect on the host immune system that offers some protection against HIV disease. Determining if this virus is related to delayed HIV disease progression in different groups of people, and understanding how the GB virus slows HIV disease may lead to new approaches to the management of HIV infection.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI058740-05
Application #
7364214
Study Section
AIDS Clinical Studies and Epidemiology Study Section (ACE)
Program Officer
Roe, Joanad'Arc C
Project Start
2004-01-01
Project End
2009-08-31
Budget Start
2008-01-01
Budget End
2009-08-31
Support Year
5
Fiscal Year
2008
Total Cost
$617,141
Indirect Cost
Name
University of Iowa
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
062761671
City
Iowa City
State
IA
Country
United States
Zip Code
52242
Bednasz, Cindy J; Venuto, Charles S; Ma, Qing et al. (2017) Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants. Ther Drug Monit 39:596-603
Verma, Anurag; Bradford, Yuki; Verma, Shefali S et al. (2017) Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202. Pharmacogenet Genomics 27:101-111
Siewe, Basile; Nipper, Allison J; Sohn, Haewon et al. (2017) FcRL4 Expression Identifies a Pro-inflammatory B Cell Subset in Viremic HIV-Infected Subjects. Front Immunol 8:1339
Verma, Shefali S; Frase, Alex T; Verma, Anurag et al. (2016) PHENOME-WIDE INTERACTION STUDY (PheWIS) IN AIDS CLINICAL TRIALS GROUP DATA (ACTG). Pac Symp Biocomput 21:57-68
Lehmann, David S; Ribaudo, Heather J; Daar, Eric S et al. (2015) Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols. Pharmacogenet Genomics 25:51-9
Moore, Carrie B; Verma, Anurag; Pendergrass, Sarah et al. (2015) Phenome-wide Association Study Relating Pretreatment Laboratory Parameters With Human Genetic Variants in AIDS Clinical Trials Group Protocols. Open Forum Infect Dis 2:ofu113
Wanga, Valentine; Venuto, Charles; Morse, Gene D et al. (2015) Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202. Pharmacogenet Genomics 25:450-61
Vardhanabhuti, Saran; Ribaudo, Heather J; Landovitz, Raphael J et al. (2015) Screening for UGT1A1 Genotype in Study A5257 Would Have Markedly Reduced Premature Discontinuation of Atazanavir for Hyperbilirubinemia. Open Forum Infect Dis 2:ofv085
Smith, Kimberly Y; Tierney, Camlin; Mollan, Katie et al. (2014) Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabine. Clin Infect Dis 58:555-63
Haas, David W; Kwara, Awewura; Richardson, Danielle M et al. (2014) Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes. J Antimicrob Chemother 69:2175-82

Showing the most recent 10 out of 66 publications